Unregulated advanced therapy medicinal products pose serious risks to health
Year: 2025
Type: other
Abstract: EMA and the Heads of Medicines Agencies (HMA) are warning the public about the dangers of unregulated advanced therapy medicinal products (ATMPs) offered to patients in the European Union. ATMPs are medicinal products that are based on genes, tissues or cells. When these medicines are regulated (i.e. authorised via EMA or approved by a national authority), they can offer important benefits for patients. The European Union has established guidelines to ensure that ATMPs meet stringent safety ...
Source: Hypotheses (OpenEdition)
DOI: 10.58079/13xy5
Author: Vroby
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6917771440
Cites:
Cited by:
Related to: